Morgan Stanley bullish on GW Pharmaceuticals

Shares of cannabinoid biopharmaceutical firm GW Pharmaceuticals (GWPH) are up 7% premarket to $49.50 on modest volume after Morgan Stanley initiates coverage with an Overweight rating and $103 PT.

Bank of America has a PT of $93, Piper Jaffray has $97 and Leerik Swann $79.

The company's lead products are GWP42006 for epilepsy, GWP42004 for Type 2 diabetes and GWP42003 for schizophrenia.

GWP42006's active ingredient is the non-psychoactive cannabinoid cannabidivarin extracted from the cannabis plant. A Phase 2 clinical trial should start later this year.

GWP42004's active ingredient is the non-psychoactive plant-derived tetrahydrocannabivarin. A Phase 2b clinical trial is expected to start in H2 2015 to compare its glycemic control efficacy versus placebo as an add-on therapy to metformin.

GWP42003's active ingredient is purified cannabidiol. A Phase 2a is underway to assess its efficacy as a first-line therapy. The study will be completed in H2 2015.

The firm also has another Epilepsy drug, Epidiolex, in development. It's active ingredient is plant-derived cannabidiol. The FDA designated it an Orphan Drug for the treatment of Dravet Syndrome and Lennox-Gastaut Syndrome.

From other sites
Comments (5)
  • StocksGrim
    , contributor
    Comments (8) | Send Message
    Just initiated a position yesterday so pleasant surprise for sure! This is a no brainer, allocate as much capital as possible in $GWPH they are light years ahead of any Cannabidiol pharmaceutical!! No brainer investment people
    22 Apr 2014, 09:13 AM Reply Like
  • Goggin
    , contributor
    Comments (59) | Send Message
    Nothing about multiple sclerosis now in-use in Europe and Canada or cancer pain Phase III research now underway.
    22 Apr 2014, 11:12 AM Reply Like
  • ParaBellum16
    , contributor
    Comments (53) | Send Message
    Been in $GWPH since Feb. '14 @ 62.50. Reason? $GWPH is one of just a tiny few companies in the cannabis space that is a REAL company with REAL product and REAL management and a REAL future. All other are just numbers on a roulette wheel. My reco: buy it, ride it, hold it, eventually I think you will profit handsomely from it. Just don't try to outguess it and trade in and out. How would you have liked to be short and see the open today? Think on that.
    22 Apr 2014, 03:14 PM Reply Like
  • Doyee51986
    , contributor
    Comments (330) | Send Message
    Nasdaq listed Cannabis Stock. Need I say more? Watch them make a killing killing epilepsy.
    22 Apr 2014, 07:44 PM Reply Like
  • Nick Cox
    , contributor
    Comments (1381) | Send Message
    I've been an share holder for a while,and there will be ups and downs,especially as most if its planned drugs are still 18 months at least from market.
    However,I think it's a great play still even at this price.
    All those cannabis companies in Colorado and California which are just pump em and dump em merchants (look at Growlife!)-as far as I can see,this is the only sane play at the moment for the cannabis for medicinal purposes idea.
    23 Apr 2014, 02:31 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs